Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06112067Not ApplicableRecruiting

Efficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders

Role: collaborator

NCT04967560Not ApplicableCompleted

The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD

Role: collaborator

NCT05884619Not ApplicableUnknown

Efficacy and Safety of Dual-target Deep Brain Stimulation for Treatment-resistant Alcohol Use Disorder

Role: collaborator

NCT05786872Not ApplicableUnknown

Efficacy and Safety of Dual-target DBS for Treatment-resistant Alcohol Use Disorder

Role: collaborator

All 4 trials loaded